Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Department of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.
J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):673-684. doi: 10.1002/jcsm.12307. Epub 2018 Jul 5.
By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin therapy.
We performed a retrospective review of 53 patients with advanced PDAC on 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin as first line therapy at Indiana University Hospital from July 2010 to August 2015. Demographic, clinical, and survival data were collected. Body composition measurement by computed tomography (CT), trend, univariate, and multivariate analysis were performed.
Among all patients, three cachexia phenotypes were identified. The majority of patients, 64%, had Muscle and Fat Wasting (MFW), while 17% had Fat-Only Wasting (FW) and 19% had No Wasting (NW). NW had significantly improved overall median survival (OMS) of 22.6 months vs. 13.0 months for FW and 12.2 months for MFW (P = 0.02). FW (HR = 5.2; 95% confidence interval = 1.5-17.3) and MFW (HR = 1.8; 95% confidence interval = 1.1-2.9) were associated with an increased risk of mortality compared with NW. OMS and risk of mortality did not differ between FW and MFW. Progression of disease, sarcopenic obesity at diagnosis, and primary tail tumours were also associated with decreased OMS. On multivariate analysis, cachexia phenotype and chemotherapy response were independently associated with survival. Notably, CT-based body composition analysis detected tissue loss of >5% in 81% of patients, while the traditional definition of >5% body weight loss identified 56.6%.
Distinct cachexia phenotypes were observed in this homogeneous population of patients with equivalent stage, diagnosis, and first-line treatment. This suggests cellular, molecular, or genetic heterogeneity of host or tumour. Survival among patients with FW was as poor as for MFW, indicating adipose tissue plays a crucial role in cachexia and PDAC mortality. Adipose tissue should be studied for its mechanistic contributions to cachexia.
根据非预期体重减轻的传统定义,约 80%的胰腺导管腺癌(PDAC)患者会出现恶病质。在这里,我们测量了接受氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂治疗的晚期 PDAC 患者的纵向体成分变化。
我们对 2010 年 7 月至 2015 年 8 月在印第安纳大学医院接受氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂一线治疗的 53 例晚期 PDAC 患者进行了回顾性分析。收集了人口统计学、临床和生存数据。通过计算机断层扫描(CT)进行身体成分测量,进行趋势、单变量和多变量分析。
在所有患者中,确定了三种恶病质表型。大多数患者(64%)有肌肉和脂肪减少(MFW),17%有单纯脂肪减少(FW),19%无减少(NW)。NW 的总中位生存期(OMS)明显改善,为 22.6 个月,而 FW 为 13.0 个月,MFW 为 12.2 个月(P=0.02)。FW(HR=5.2;95%置信区间=1.5-17.3)和 MFW(HR=1.8;95%置信区间=1.1-2.9)与 NW 相比,死亡风险增加。与 NW 相比,FW 和 MFW 的 OMS 和死亡率没有差异。疾病进展、诊断时的肌肉肥胖症和原发尾肿瘤也与 OMS 降低有关。多变量分析显示,恶病质表型和化疗反应与生存独立相关。值得注意的是,基于 CT 的身体成分分析在 81%的患者中检测到>5%的组织丢失,而>5%的体重减轻的传统定义仅识别出 56.6%。
在这组具有相同分期、诊断和一线治疗的同质患者中观察到不同的恶病质表型。这表明宿主或肿瘤存在细胞、分子或遗传异质性。FW 患者的生存与 MFW 患者一样差,表明脂肪组织在恶病质和 PDAC 死亡率中起着关键作用。应研究脂肪组织在恶病质中的机制贡献。